Research programme: monoterpene analogues - DOR BioPharma/University of Wisconsin-Madison
Latest Information Update: 07 Dec 2006
At a glance
- Originator DOR BioPharma; University of Wisconsin-Madison
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 10 Dec 2001 Endorex Corporation is now called DOR BioPharma
- 21 May 1999 Preclinical development for Cancer in USA (Unknown route)